HER2-POSITIVE BREAST CANCER
Clinical trials for HER2-POSITIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HER2-POSITIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for HER2-POSITIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo shows promise for Hard-to-Treat breast cancer
Disease control CompletedThis study tested a new drug, copanlisib, combined with the standard drug trastuzumab in 26 women with advanced HER2-positive breast cancer that had stopped responding to previous treatments. The goal was to find the safest dose and see if the combination could shrink tumors or s…
Matched conditions: HER2-POSITIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Cancer Trials Ireland • Aim: Disease control
Last updated May 17, 2026 00:51 UTC
-
Real-World study shows Tucatinib's impact on advanced breast cancer
Disease control CompletedThis study looked at how well the drug tucatinib works in everyday medical practice for people with advanced HER2-positive breast cancer who have already tried at least two other treatments. Researchers tracked 49 adults in Germany and Austria to see how their quality of life cha…
Matched conditions: HER2-POSITIVE BREAST CANCER
Sponsor: iOMEDICO AG • Aim: Disease control
Last updated May 17, 2026 00:49 UTC
-
Could a custom vaccine boost breast cancer treatment?
Disease control CompletedThis early-phase study tested a personalized vaccine made from a patient's own immune cells, designed to target HER2-positive breast cancer. 31 adults with stage II or III breast cancer received the vaccine alongside standard chemotherapy before surgery. The goal was to see if th…
Matched conditions: HER2-POSITIVE BREAST CANCER
Phase: EARLY_PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New study tests targeted therapy for aggressive breast cancer in egyptian women
Disease control CompletedThis study looked at how well anti-HER2 drugs work in Egyptian women with HER2-positive breast cancer, an aggressive type. Researchers followed 80 patients to see if single or combination therapy improved survival and safety. The goal was to understand real-world effectiveness in…
Matched conditions: HER2-POSITIVE BREAST CANCER
Sponsor: Deraya University • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
New drug combo shows promise against tough breast cancer
Disease control CompletedThis study tested a combination of two drugs, tucatinib and trastuzumab deruxtecan (T-DXd), in 70 people with advanced HER2+ breast cancer that had spread or couldn't be removed by surgery. The goal was to see how well the drugs shrank tumors and what side effects occurred. Parti…
Matched conditions: HER2-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated May 06, 2026 16:13 UTC
-
Real-world data reveals how often breast cancer patients stop or adjust T-DXd therapy
Knowledge-focused CompletedThis study looked at 22 adults with advanced HER2-positive or HER2-low breast cancer who were taking the drug trastuzumab deruxtecan (T-DXd). Researchers wanted to see how often patients stopped treatment early or needed dose changes in everyday medical practice. The goal was to …
Matched conditions: HER2-POSITIVE BREAST CANCER
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated May 15, 2026 11:56 UTC
-
Researchers review Real-World use of neratinib in early breast cancer
Knowledge-focused CompletedThis study reviewed medical records of 111 adults with early-stage HER2-positive breast cancer who received the drug neratinib as extra treatment after their main therapy, through a special early access program in Europe. The goal was to describe the patients' ages, genders, heal…
Matched conditions: HER2-POSITIVE BREAST CANCER
Sponsor: Pierre Fabre Medicament • Aim: Knowledge-focused
Last updated May 14, 2026 12:04 UTC